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The development of the oral squamous cell carcinoma (OSCC) is a multistep process that requires the accumulation of multiple
genetic alterations usually preceded by detectable mucosal changes, most often leukoplakias and erythroplakias. The clinical
appearance of oral precancerous lesions and their degree of epithelium dysplasia suggests the malignization potential. Several
techniques have been developed to improve the clinical and cytological diagnosis of oral precancerous lesions. The present paper
reviews the main techniques used to improve premalignant lesion diagnosis.
1.Biopsy andCytology
Oral cancer ranks as the sixth most common malignancy
worldwide, 90% of which consists of squamous cell carci-
noma [1–5]. Morbidity and mortality have not decreased
over the past 50 years. Oral cancer early detection, mainly
that of squamous cell carcinoma, is crucial to improve the
patient’s survival rate [1, 3–10]. The clinical diagnosis of oral
precancerous lesions, leukoplakias and erythroplakias, is one
of exclusion. The lesions to be excluded are those belonging
to other conditions, such as lichen planus (acknowledging
that it has a malignant potential itself), lupus erythematosus,
leukoedema,whitespongenevus,andotherlesionsforwhich
an etiology can be established, such as frictional keratosis,
cheek/lip/tongue biting, contact lesions, and smoker’s palate
[11]. In many cases, a biopsy is mandatory so that such
lesions can be discarded. Currently, histological criteria (dys-
plasia presence and degree) represent the gold standard in




Cytopathology is the microscopic study of cell samples col-
lectedfrommucosalsurfacesobtainedbyexfoliativecytology
(via smears, scrapings, or lavage) or from internal sites via
ﬁne-needle aspiration [13]. Exfoliative cytology was ﬁrst
designed for cervical cancer cell early detection [14–18]a n d
it has been primarily applied in oral medicine practice to
detect early changes in oral mucosa related to malignancy.
Furthermore, this exam has also been used in the diagnosis
of certain types of oral lesions, most of which related to viral
and fungal diseases [14].
Exfoliative cytology is performed with cytobrushes so as
to obtain good-quality smear that includes cells from deeper
layers of epithelium, especially of squamous intraepithelial
lesions [19]. Cytological technique improvements that led to
the development of a liquid-based preparation have renewed2 Journal of Oncology
interest in the use of this approach as an auxiliary tool in oral
lesion diagnosis [14].
According to Mehrotra et al. [19], sensitivity and speci-
ﬁcity of conventional exfoliative cytology in carcinoma’s sus-
pected lesions, ranged between 76.8%–100%, and 88.9%–
100%, respectively, in a review of 22 articles. In another
paper, the cytological study of oral cavity’s cells was shown
to be suitable for routine application in population screening
programs, for early analysis of suspect lesions, and for
pre-and posttreatment monitoring of conﬁrmed malignant
lesions [16].
In liquid-based cytology, the cytobrush with the sample
is transported in a vial containing preservative ﬂuid which
allows the immediate ﬁxation of cells so that all the scraped
material can be used, providing high cellularity slides
dispersed in a thin and homogeneous layer on a clear back-
ground, thus facilitating abnormal cell identiﬁcation [14,
17, 20]. These characteristics help to establish an early oral
cancer diagnosis [17, 20–23]. The use of this technique has
signiﬁcantly reduced the number of unsatisfactory slides,
diminishing false negative results and has increased sensitiv-
ity and speciﬁcity when compared to conventional cytology
[14, 21]. According to Nanove [24], the sensitivity for this
technique is 95,1%, and the speciﬁcity is 99%. In another
study [19], it was showed the number of inadequate samples
was reduced 8,8%. However, it requires more sophisticated
laboratory equipment as well as a better-trained staﬀ to
handle, process, and analyze the samples properly [20].
The cells obtained from exfoliative cytology can be used
formolecularanalysis.Somemolecularmarkersmayprovide
additionalinformationthatwillbeusefulinmalignantlesion
early diagnosis. The main markers used in cytological anal-
ysis are Ki-67 [16,p a g e5 3 ] ,[ 19, 22], DNA ploidy status
(chromosomal pairing) [18, 25], epigenetic changes (hyper-
methylation of the promoter region), and genomic instabil-
ity, such as loss of heterozygosity instability (LOH) [22, 26]
and microsatellite (MSI) [22].
3. Cytomorphometry: Computer-Assisted
AnalysisBrushBiopsy
Cytomorphometry, computer-assisted analysis brush biopsy
(Oral CDx Laboratories, Suﬀern, N.Y), is a method used in
the analysis of cellular samples collected by brush biopsy,
a disposable specialized circular plastic brush that collects
transepithelial cellular samples composed of free cells and
clusters [13, 19]. The clinician rubs or rotates the brush
against the lesion until pinpoint bleeding is absorbed [27].
The samples are ﬁxed onto a glass slide and sent to a labo-
ratory where they are stained (via a modiﬁed Papanicolaou
test), scanned, and analyzed microscopically by means of
a computer-based imaging system that can rank cells on the
basis of their degree of abnormal morphology [13]. The ana-
lytical results and representative examples are then referred
to a pathologist [19]. Results are reported as “negative” or
“benign,” “positive” or “atypical.” Abnormal diagnoses have
included “positive” (deﬁned as deﬁnitive cellular evidence
of epithelial dysplasia or carcinoma) and “atypical” (deﬁned
as abnormal epithelial changes of uncertain diagnostic sig-
nificance) results [13].
After the automated analysis, the pathologist can recom-
mend the clinical practitioner to follow further procedures
(clinical control, repeated brush biopsy, surgical biopsy, etc.)
[19]. Several papers have been written on this technique
[19, 28–37], but few have evaluated its performance in the
prevention of oral cancer [13, 30–32, 34, 38–40]. These
articles have reported sensitivity values that ranged from
88% [39] to 100% [32] and 25% [38] to 96% speciﬁcity [39].
This test has been chosen to assess lesions the practitioner
might not investigate further and is not recommended for
the assessment of clinically suspicious lesions for which the
practitioner would normally perform conventional biopsy
[13, 17].
Oral brush biopsy, as a noninvasive diagnostic method,
can be useful for oral mucosal lesion early detection. The
occurrence of positive ﬁndings, or lesion progression despite
negativeﬁndings,signalsthatthepatientneeds tobereferred
to a specialized clinic where a surgical biopsy should be
performed, followed by histopathologycal analysis. Histopa-
thologyremainsthegoldstandardforthedeﬁnitivediagnosis
of oral malignant lesions [36, 41].
4. ClinicalTissueStainingTechnique
4.1.VitalIodineStain. Vitaliodinestain(3%Lugolsolution)
can be used prior to biopsy and resection and is useful in
the determination of the best incision area. This technique
has been used in upper gastrointestinal tract endoscopy
routine, as well as in cervix examination and in esophageal
cancer [42]. Its principle is based on the binding of iodine
to glycogen granules in the cytoplasm, resulting in a black-
brown tissue color. In cancer cells, where the glycolysis is
elevated [42], this method results in unstained areas whereas
thenormalmucosaisstained[42].Inastudywith54patients
[42], with oral squamous cell carcinoma or oral potentially
malignant lesions, where the authors made surgical margins
of 5–8mm from the border of the stained lesion with vital
iodine stain, it was shown that 98,1% has no recurrence after
a median followup of 15 months.
4.2. Toluidine Blue Staining (TBlue Staining). Toluidine Blue
(also known as tolonium chloride) is a vital metachromatic
dye of the thiazine group that has been eﬀectively used in
nuclear staining because of its binding to DNA nucleus acid
[2, 3, 7]. It has been used for decades as an aid in epithelium
dysplasia identiﬁcation [2, 10] and appears to improve pre-
cancerous lesion visualization by showing high-risk areas
(areas of high cell proliferation), therefore guiding biopsy
[2, 3, 7, 9, 10]. However, most studies have had problems
with the absence of randomized control care and methodol-
ogy[2,3,7,9,10].Theproceedingstartswithatopicalappli-
cation of TBlue on the lesion with the aid of a swab or cotton
applicator, and the more intense TBlue staining areas should
be the ones elected to be biopsied. TBlue seems to be highly
sensitive but has low speciﬁcity, since it also stains benign
and common lesions which involve inﬂammation [2, 7].Journal of Oncology 3
TBlue is an easy and cheap technique, causes no harm to the
patient, and may help to perform a careful clinical exami-
nation [3, 7]. False negative staining is very rarely observed
in squamous cell carcinoma, but inﬂammatory lesions can
contribute to false positive outcomes [7]. Some works [7,
10] have shown the sensitivity and speciﬁcity vary from
38%–98% and 9%–93%, respectively.
5. Chemiluminescence Technique
5.1. Chemiluminescence Light. The chemiluminescence tech-
nique (ViziLite (Zila Pharmaceuticals, Phoenix, Arizona)) is
an exam that was approved in 2002 in the USA. It serves the
purpose of improving the identiﬁcation, visualization, and
monitoring of oral precancerous lesions [1, 4, 8, 10, 43], and
consists of the emission of light from a chemical reaction
between hydrogen peroxide and acetylsalicylic acid inside
a capsule light stick [4, 8, 44]. The use of a 1% acetic acid
solution for washing and cleaning the oral mucosa for about
1 minute before chemiluminescence light is recommended.
The action of the stick holds good for approximately 10
minutes [1, 3, 4, 44]. This reaction emits a blue/white light
(430–580nm) whose principle is based on the reﬂective
properties of tissues that present cellular alterations such as
a higher nuclear/cytoplasmatic rate. The “acetowhite” lesion
is more deﬁned and sharper, whereas the normal tissue is
dark [1–4, 8–10, 44].
This seems to be an easy, safe and noninvasive system
capable of helping the dentist to better visualize lesions, as
well as its edges [3, 8, 44]. Another point to consider is that
the lesion seems to be bigger under chemiluminescence light
[44]. One disadvantage is that this system is expensive and
a stick is used for each patient. Furthermore, chemilumines-
cence light seems to be nonspeciﬁc as it does not identify the
lesion etiology—whether inﬂammatory, neoplastic benign,
or neoplastic malign—and this could lead to unnecessary
biopsies [2, 8, 44].
This system is useful for clinical examination, inasmuch
as it improves the lesion visualization [9], especially when
used in association with the Toluidine Blue solution to mark
the lesions to posterior biopsy [2, 8]. It is known that
acetic acid wash can provide a more accurate diagnosis than
chemiluminescence light [2].
The ViziLite tool enhance intraoral visualization of white
lesions, however it is not able to discriminate between kera-
totic, inﬂammatory, malignant, or potentially malignant oral
mucosal white lesions [8, 9, 45]. The main advantage of this
technique is that it signiﬁcantly improves the sharpness of
the lesions’ margins [8, 9, 45].
6. Light Emission Technique
The Light Emission Technique (Microlux DL (AdDent, Dan-
bury, Conn.)) seems to operate on a principle of light
emission similar to that of chemiluminescence light and
helps to sharpen the lesion edges as well as to improve
visualization [2, 43]. In this method, the patient ﬁrst needs
to have a 1% acetic acid mouthwash, and then a battery-
powered light source is used. An advantage of this system
is that it is reusable [2, 8, 10, 43]. Another similar system
u s e saL e d( O r a s c o p t i cD K( O r a s c o p t i c ,aK e r rC o m p a n y ,
Middleton, Wis.)) with a rechargeable battery to screen the
oral mucosa and claims to improve visualization [10]. In
as t u d y[ 43] to assess the eﬃcacy of acetic acid mouthwash
and diﬀused light illumination (Microlux/DL), as a diag-
nostic tool in the visualization of oral mucosal potentially
malignant lesions, Microlux/DL showed a sensitivity of
77.8% and a speciﬁcity of 70.7%, with a positive predictive
value of 36.8%. According to the authors [43], Microlux/DL
was able to enhance lesion visibility; however, it is a poor
discriminator for inﬂammatory, traumatic, and malignant
lesions.
The Narrow-emission tissue ﬂuorescence (VELscope
(LED Dental Inc. White Rock, British Columbia, Canada))
technique involves tissue exposure to diﬀerent wavelengths
(400 to 460nm) in order to observe diﬀerences between nor-
mal and abnormal mucosa [2, 46]. This system involves the
cell answer (autoﬂuorescence due to cellular ﬂuorophores)
after excitation [2–4, 10] .T h ea b n o rm a lt i s s u eh a sad i ﬀerent
ﬂuorophore concentration that results in changes in color
[4]. This method uses a small optic ﬁber and consequently
does not cover the entire mouth, so it is employed only for
isolatedlesions[2],lesionedge,andcancerizationﬁelddeter-
mination [4]. While the normal mucosa glows and emits
color (pale green), the abnormal mucosa shows decreased
levels of ﬂuorescence and acquires a dark magenta, brown,
or black color, as it absorbs ﬂuorescence [2, 4, 6, 47]. This
technique seems to be helpful in lesion detection, but it
is useless in the diﬀerentiation of malignant from benign
lesions [2, 3, 6]. Despite its applicability, the system is
expensive, and color interpretation is diﬃcult, which could
lead to a erroneous diagnosis [6]. Some studies in the lit-
erature [4, 6] referred this technique as having sensitivity
values from 97% to 98% and speciﬁcity from 94% to 100%.
Multispectral ﬂuorescence and reﬂectance (Identaﬁ 3000
(Trimira, Houston, Texas)) is a new technique based on the
tissue ﬂuorescence principle [3, 46] which uses three types
of lights: white, violet (405nm), and amber (560nm) [46].
According to the manufacturer, white and violet lights use
the same principle as tissue reﬂex and ﬂuorescence, while
amber light improves vascular architecture visualization in
normal and abnormal tissue [48]. Normal tissue appears
deﬁned, while the abnormal tissue has a diﬀuse vasculature
[48]. According to the manufacturer, it is reusable [48]. This
method has not been studied yet.
7. Conclusions
In this paper we approached diﬀerent techniques which
may be useful in the diagnosis of precancerous lesions. It
is shown their applications and limitations. However, many
possibilities are available, and it is concluded that the most
reliable method of diagnosis is still the biopsy followed by
histopathological examination.4 Journal of Oncology
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